Evolus, Inc. EOLS

Updated: 10 Aug 2026

NASDAQ | Biotech | Medical aesthetics / biotechnology

No signal published yet

We already track Evolus and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Evolus free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Medical aesthetics / biotechnology
We're already tracking Evolus, Inc. — here are the latest events we've registered

Recent News

  • On August 5, 2026, Evolus reported its second quarter 2026 financial results with global net revenue reaching $84.1 million, a 21% increase year-over-year. The company achieved its third consecutive quarter of positive adjusted EBITDA at $4.7 million and raised its full-year 2026 revenue guidance to between $330 million and $337 million. Evolus also announced an exclusive U.S. licensing agreement for the skin quality product Profhilo.

What Firelda Watch includes for Evolus, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Evolus, Inc. will be delivered in the same format.

Want to follow Evolus, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Evolus free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Evolus, Inc. EOLS
Evolus — follow and we'll monitor it
Follow Evolus free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.